A number of pharmaceutical stocks soared, and humanwell pharmaceutical and Beida pharmaceutical reached new annual highs

[pharmaceutical network pharmaceutical stock market] on February 24, several pharmaceutical stocks, such as Xinhua Pharmaceutical, humanwell pharmaceutical, Beida pharmaceutical, etc., showed an upward trend In addition, humanwell pharmaceutical, Beida pharmaceutical and other pharmaceutical stocks reached new highs The author briefly combed this for industry reference only Xinhua Pharmaceutical Co., Ltd rose 0.7% in the morning of February 24 In the morning of that day, Xinhua Pharmaceutical Co., Ltd rose 0.7%, a new high in nearly eight months, to 8.68 yuan, with a turnover of 1.49 million yuan, a turnover rate of 0.04%, an amplitude of 0.35%, and a volume ratio of 2.96 According to the company's third quarter report in 2019, the company's operating revenue is 4.399 billion yuan, net profit is 239 million yuan, earnings per share is 0.38 yuan, and P / E ratio is 18.10 In terms of agency rating, in the past six months, one securities firm has given suggestions on increasing its holdings According to the data, Xinhua Pharmaceutical's main business is to develop, manufacture and sell chemical APIs, pharmaceutical preparations, chemicals and other products Humanwell medicine rose 0.55% in the morning of February 24 Humanwell medicine rose 0.55% to an annual high of 14.65 yuan, with a turnover of 11.35 million yuan, a turnover rate of 0.06%, an amplitude of 1.24%, and a volume ratio of 2.02 According to the company's third quarter report in 2019, the company's operating revenue is 16.104 billion yuan, net profit is 746 million yuan, earnings per share is 0.51 yuan, and P / E ratio is - 8.72 In terms of agency rating, in the past half a year, one securities firm has given neutral suggestions and one securities firm has given buying suggestions According to the data, the main business of humanwell pharmaceutical is R & D, production, sales and technical services of products and technologies such as medicine and medical devices In early trading today, HongRi Pharmaceutical (300026) rose 5.01% to 5.03 yuan, with a turnover of 126 million yuan, a turnover rate of 1.05%, an amplitude of 4.38%, and a volume ratio of 4.20 HongRi pharmaceutical industry rose 5.01% and that of traditional Chinese medicine industry where HongRi pharmaceutical industry is located rose 0.65% as a whole The leading gainer is HongRi pharmaceutical According to the company's third quarter report in 2019, the company has realized operating revenue of 3.602 billion yuan, net profit of 516 million yuan, earnings per share of 0.17 yuan and P / E ratio of 54.57 yuan The company has no agency rating According to the data, the main business of HongRi pharmaceutical is the R & D, production and sales of drugs and medical devices Beida Pharmaceutical Co., Ltd rose 0.52% in the morning of February 24 In the morning of that day, Beida Pharmaceutical Co., Ltd rose 0.52% to an annual high of 83.50 yuan, with a turnover of 103.46 million yuan, a turnover rate of 0.33%, an amplitude of 3.25%, and a volume ratio of 3.37 The chemical and pharmaceutical industry in which Beida pharmaceutical industry is located rose 0.56% as a whole According to the company's third quarter report in 2019, the company has realized operating revenue of RMB 1.243 billion, net profit of RMB 199 million, earnings per share of RMB 0.50 and P / E ratio of 153.08 In terms of agency rating, in recent half a year, eight securities companies have given suggestions on increasing their holdings and eight securities companies on buying According to the data, the main business of Beida pharmaceutical is drug research and development, production and sales Renhe Pharmaceutical Co., Ltd rose 1.26% in the morning of February 24 In the morning of that day, Renhe Pharmaceutical Co., Ltd rose 1.26% to a three-month high of 7.23 yuan, with a turnover of 10.07 million yuan, a turnover rate of 0.12%, an amplitude of 0.98%, and a volume ratio of 5.43 In addition, Renhe pharmaceutical's traditional Chinese medicine industry, the overall growth rate was 0.37% According to the company's third quarter report in 2019, the company has realized operating revenue of 3.555 billion yuan, net profit of 440 million yuan, earnings per share of 0.36 yuan and P / E ratio of 15.98 yuan In terms of agency rating, in recent half a year, one securities firm has given suggestions on increasing its holdings, and two securities firms have given suggestions on buying According to the data, Renhe pharmaceutical is mainly engaged in the production and operation of Chinese and Western medicines such as capsules, granules, tablets, suppositories, ointments, liniments and other related health products Step pharmaceutical rose 4.0% on February 24 By the time of publication, step pharmaceutical rose 4.0% to a new high of 21.84 yuan in nearly four months, with a turnover of 407.71 million yuan, a turnover rate of 1.66%, an amplitude of 3.57%, and a volume ratio of 2.62 In addition, the industry of traditional Chinese medicine in which step pharmaceutical is located, the overall increase was 0.38% According to the company's third quarter report in 2019, the company's operating revenue is 10.242 billion yuan, net profit is 1.349 billion yuan, earnings per share is 1.21 yuan, and P / E ratio is 11.86 yuan The company has no agency rating According to the data, the main business of step pharmaceutical is R & D, production and sales of Chinese patent medicine Hanyu Pharmaceutical Co., Ltd rose 2.77% on February 24 As of the press release, Hanyu Pharmaceutical Co., Ltd rose 2.77% to a new high of 6.68 yuan in nearly two months, with a turnover of 81.7 million yuan, a turnover rate of 2.06%, an amplitude of 3.08%, and a volume ratio of 1.53 According to the company's third quarter report in 2019, the company has achieved an operating revenue of 557 million yuan, a net profit of - 80.0441 million yuan, a per share income of - 0.09 yuan and a P / E ratio of - 8.34 yuan The company has no agency rating According to the data, Hanyu pharmaceutical is mainly engaged in chemical pharmacy and medical devices Jiangzhong Pharmaceutical Co., Ltd rose 0.23% in the morning of February 24 In the morning of that day, Jiangzhong Pharmaceutical Co., Ltd rose 0.23%, reaching a new high of nearly one month, at 13.16 yuan, with a turnover of 7.05 million yuan, a turnover rate of 0.10%, an amplitude of 0.84%, and a volume ratio of 2.65 According to the company's third quarter report in 2019, the company has realized operating revenue of RMB 1.704 billion, net profit of RMB 382 million, earnings per share of RMB 0.73 and P / E ratio of 13.83 The company has no agency rating Data shows that the main business of Jiangzhong pharmaceutical is TCM OTC, health products production and sales.